Sanofi Ventures has announced an additional multi-year commitment from Sanofi (EURONEXT: SAN and NASDAQ: SNY), with an increase in capital to more than $750m to the evergreen venture fund.
In addition to serving as a financial partner to top-tier early-to-mid-stage portfolio companies, the fund supports future efforts for business development and M&A opportunities within Sanofi. The additional capital will also accelerate the expansion and investment capacity of the Sanofi Ventures investment team on a global scale.Led by Jason P. Hafler, Managing Director, Sanofi Ventures invests in top innovators working in areas including immunology and inflammation, rare diseases, oncology, cell and gene therapy, vaccines, and digital health and data science. The team partners across all stages of the private company lifecycle, from Seed to Series B and beyond, leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value. In 2022, Sanofi Ventures closed 10 investments in global therapeutic and digital areas of strategic interest to Sanofi. Since its inception, 80% of investments have been in biotherapeutics and 20% have been in digital health companies.11/01/2022
